Last reviewed · How we verify
Cord Blood Nucleated cells
At a glance
| Generic name | Cord Blood Nucleated cells |
|---|---|
| Sponsor | HONYA Medical Co Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II (PHASE2)
- Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) (PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (NA)
- Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation (PHASE2)
- Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study (NA)
- Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT (PHASE3)
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy (PHASE2)
- IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cord Blood Nucleated cells CI brief — competitive landscape report
- Cord Blood Nucleated cells updates RSS · CI watch RSS
- HONYA Medical Co Ltd portfolio CI